Priovant enrolls first patients in Phase 3 cutaneous sarcoidosis trial

August 6, 2026 7:00 AM

Priovant Therapeutics announced the enrollment of the first patients in its Phase 3 BEACON+ study evaluating brepocitinib for cutaneous sarcoidosis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found